Bioventus (BVS) Stock Forecast & Price Target

Bioventus Inc reported a revenue of $55.5 million in its surgical solutions segment, marking a growth of 3.4% as reported and 3.1% on a constant currency basis, with a notable 10.3% growth excluding divestitures, driven by enhanced commercial effectiveness. The pain treatments business showcased exceptional performance with $79.7 million in revenue, while ongoing investments aimed at accelerating growth in several key areas are anticipated to bolster results in the latter half of 2026 and into 2027 and beyond. Management projects low-double-digit growth for the surgical solutions segment in 2026, with expectations for significant improvements in adjusted EBITDA margins, indicating a positive financial outlook for Bioventus through 2030.

The financial performance of Bioventus indicates a concerning trend, particularly within its Restorative Therapies segment, which experienced a significant revenue decline of 26.0% in the latest reporting period, contrasting sharply with earlier forecasts. Additionally, despite a reduction in the leverage ratio, the company's adjusted EBITDA margins are anticipated to remain flat or decline slightly in the coming years, signaling potential challenges in cost management and profitability. Furthermore, the gross margin was reported at 68.9%, falling below estimates, which further highlights the ongoing pressures on operating efficiency and financial stability.